- Home
- PHIO vs CYCC Comparison
PHIO vs CYCC Comparison
Compare PHIO & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- CYCC
- Stock Information
- Founded
- PHIO 2011
- CYCC 1992
- Country
- PHIO United States
- CYCC United States
- Employees
- PHIO N/A
- CYCC N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- PHIO Health Care
- CYCC Health Care
- Exchange
- PHIO Nasdaq
- CYCC Nasdaq
- Market Cap
- PHIO 2.3M
- CYCC 2.3M
- IPO Year
- PHIO N/A
- CYCC N/A
- Fundamental
- Price
- PHIO $2.61
- CYCC $0.34
- Analyst Decision
- PHIO Strong Buy
- CYCC Buy
- Analyst Count
- PHIO 1
- CYCC 2
- Target Price
- PHIO $36.00
- CYCC $11.00
- AVG Volume (30 Days)
- PHIO 30.8K
- CYCC 431.0K
- Earning Date
- PHIO 11-14-2024
- CYCC 11-12-2024
- Dividend Yield
- PHIO N/A
- CYCC N/A
- EPS Growth
- PHIO N/A
- CYCC N/A
- EPS
- PHIO N/A
- CYCC N/A
- Revenue
- PHIO N/A
- CYCC $74,000.00
- Revenue This Year
- PHIO N/A
- CYCC N/A
- Revenue Next Year
- PHIO N/A
- CYCC $88.68
- P/E Ratio
- PHIO N/A
- CYCC N/A
- Revenue Growth
- PHIO N/A
- CYCC N/A
- 52 Week Low
- PHIO $2.17
- CYCC $0.32
- 52 Week High
- PHIO $10.35
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- PHIO 48.74
- CYCC 37.88
- Support Level
- PHIO $2.58
- CYCC $0.33
- Resistance Level
- PHIO $2.91
- CYCC $0.42
- Average True Range (ATR)
- PHIO 0.21
- CYCC 0.04
- MACD
- PHIO 0.01
- CYCC 0.01
- Stochastic Oscillator
- PHIO 26.76
- CYCC 8.21
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.